Carrier Screening Market by Screening Type (Targeted Disease Carrier and Expanded Carrier [Customized Panel Testing and Predesigned Panel Testing]), Medical Condition (Pulmonary, Genetic Disorders, Neurological, Hematological, and Others), Technology (Polymerase Chain Reaction, Microarrays, DNA Sequencing, and Others), End-user (Reference Laboratories, Clinics, Hospitals, Physicians, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The global carrier screening market size was valued at USD 2.1 Bn in 2022 and is likely to reach USD 7.1 Bn by 2031, expanding at a CAGR of 14.1% during 2023 – 2031. The market growth is attributed to the growing emphasis on the prevention and early detection of diseases coupled with the rising application in the detection of genetic disorders.
Carrier screenings are tests that determine if an individual carries a gene for certain genetic disorders. It enables finding the probability of having a genetic disorder in newborns. Tests are carried out by collecting samples from the inside of the cheek in the form of saliva, blood, or tissues. Carrier screening tests are widely carried out in genetic disease diagnostics.
A person who inherits a recessive variant gene for a genetic mutation or trait is known as carrier. The carrier may not display the trait or symptoms of a disease. Yet, carriers are likely to pass on the allele to their offspring. If the recessive allele is inherited from both parents, the offspring may express the genetic disorder. The probability of two carriers having a child with the inherited disease is as high as up to 25%. The recessive nature of genes is responsible for such a phenomenon.
Positive test results mean having the genes that may cause genetic disorders whereas negative test results mean not having the gene. Tests are carried out on the partner who is more likely to be the carrier. If the test results are negative no further testing is recommended. For a positive test result, the other partner is tested. The carrier screening tests are carried out before or during pregnancy.
The COVID-19 pandemic disrupted the overall healthcare service with the abrupt closing of businesses due to the lockdown restrictions imposed by the government across the world. This resulted in reduced human resources in the healthcare facilities including laboratories, hospitals, and clinics. However, the demand for carrier screening services declined due to disruptions in genetic counseling for newborn screening (NBS) programs.
Carrier Screening Market Dynamics
Major Drivers
Growing demand for the early detection of diseases is expected to drive the market. Early detection reduces the long-term complications and offers the best chance of cure. Rising prevalence of genetic diseases and increasing innovations in diagnosis for cost-effective testing are likely to fuel the market.
Existing Restraints
High costs associate with carrier screening tests is anticipated to hinder the market. Moreover, the scarcity of skilled professionals and the lack of standard guidelines for carrier screening are likely to restraints the market.
Emerging Opportunities
Growing investments in healthcare analytical testing services and preventive healthcare facilities are expected to provide lucrative growth opportunities for the carrier screening market. Government across the globe constantly rising their funding in healthcare sector for developing superior healthcare facilities. Moreover, rising launch of novel tests for diagnosis accelerates the market.
Scope of the Carrier Screening Market Report
The report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Carrier Screening Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016 – 2021 |
Forecast Period |
2023 – 2031 |
Segmentation |
Screening Type (Targeted Disease Carrier and Expanded Carrier [Customized Panel Testing and Predesigned Panel Testing]), Medical Condition (Pulmonary, Genetic Disorders, Neurological, Hematological, and Others), Technology (Polymerase Chain Reaction, Microarrays, DNA Sequencing, and Others), and End-user (Reference Laboratories, Clinics, Hospitals, Physicians, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
GRAIL, LLC.; Bio-Techne; ASURAGEN, INC.; Laboratory Corporation of America Holdings; Otogenetics; Thermo Fisher Scientific Inc.; Myriad Genetics, Inc.; Natera, Inc.; Cepheid; F.Hoffmann-La Roche Ltd.; MedGenome; GeneTech; CENTOGENE N.V.; Autogenomics Inc.; Danaher Corporation; Eurofins Scientific; 23Andme Inc.; Abbott Laboratories; Oxford Nanopore; and Illumina. |
Market Segment Insights
Based on screening type, the market is bifurcated into targeted disease carrier and expanded carrier. The expanded carrier segment is further classified into customized panel testing and predesigned panel testing. The expanded carrier segment is projected to expand at a considerable CAGR during the forecast period due to the increasing use of new throughput technologies such as microarray and sequencing technologies. It detects multiple disorders from a single sample and helps in determining the risk of having a child with a genetic disease.
The expanded carrier screening facilitated with new genetic testing technologies, which allows for a more thorough determination of the risks of a large number of diseases. It has the ability to detects whether the parents are unknowingly carrying genetic conditions that may be passed to their children. It offers screening for multiple autosomal and X-linked recessive disorders.
The targeted disease carrier segment is anticipated to gain significant shares of the market in the coming years, owing to the rising focus towards testing for specific ethnicity, groups, or race. Genetic disorders can be detected in individuals with a family history for specific genetic disorders through targeted disease carrier screening. The ability to identify any disease at an early stage is likely to contribute to segment growth.
In terms of medical condition, the market is divided into pulmonary, genetic disorders, neurological, hematological, and others. The genetic disorders segment is projected to hold a large share of the market during the projected period due to the increasing cases of recessive disorders that affects newborns. According to the American College of Obstetricians and Gynecologists, carrier screening should be mandatory for every pregnant woman to identify recessive disorders at an early stage.
Cystic fibrosis is a major concern affecting newborns. There is 25% chance of a newborn being a carrier if both parents are carriers. Spinal muscular atrophy (SMA) is a common recessive disorder with a high probability of 98% of affected cases inheriting a non-working copy from their parents due to genetic disorders. As per a study completed by Egyptian Journal of Medical Human Genetics in 2022, the detection frequency of SMA carriers is high and is a key genetic cause of death among newborns. Thus, the increasing demand for spinal muscular atrophy treatment is further likely to propel the segment.
On the basis of technology, the carrier screening market is fragmented into polymerase chain reaction, microarrays, DNA sequencing, and others. The DNA sequencing segment held a large share of the market in 2021 and is expected to expand at a significant growth rate during the projection period due to a surge in the prevalence of genetic diseases. It is a highly accurate molecular test having capability to detect carriers across all ethnic groups. It detects all types of genomic DNA alterations. Growing awareness regarding genetic testing in the form of molecular diagnostics and next-generation sequencing with the implementation of technology is expected to fuel the segment.
Based on end-user, the market is categorized into reference laboratories, clinics, hospitals, physicians, and others. The hospitals segment is projected to expand at a considerable CAGR during the assessment period owing to the increasing patient preferences for genetic testing in hospitals due to the wide availability of doctors and multi-specialty services. The ease of accessibility to hospitals is further likely to propel the market.
The laboratories segment is anticipated to hold a key share of the market in the coming years due to increasing investments by strategic investors to meet the growing demand for genetic testing. The investments are aimed at expanding specialized testing facilities and faster turnaround times. For instance, in November 2022, Redcliffe Labs invested nearly USD 10 Mn to expand its genetic testing capabilities.
In terms of region, the global carrier screening market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, owing to the high prevalence of genetic diseases and increase in the number of market players that provides screening tests in the region.
According to the World Health Organization (WHO), genetic illness is the primary cause of newborn mortality in the US. In 2019, nearly 2.4 Mn newborn babies died within the first month. Easy access to advanced screening techniques due to the presence of well-established healthcare infrastructure is further anticipated to fuel the market in the region.
The market in Asia Pacific is projected to grow at a rapid pace in the coming years owing to the growing demand for carrier screening tests from countries such as Japan, India, and China. The regional market growth is further attributed to the increasing government funding to support genetic tests and the rising emphasis on early disease detection & prevention due to the growing awareness regarding genetic diseases.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Carrier Screening Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Carrier Screening Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Carrier Screening Market - Supply Chain
4.5. Global Carrier Screening Market Forecast
4.5.1. Carrier Screening Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Carrier Screening Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Carrier Screening Market Absolute $ Opportunity
5. Global Carrier Screening Market Analysis and Forecast by End Users
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by End Users
5.2.2. Y-o-Y Growth Projections by End Users
5.3. Carrier Screening Market Size and Volume Forecast by End Users
5.3.1. Reference Laboratories
5.3.2. Clinics
5.3.3. Hospitals
5.3.4. Physicians
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by End Users
5.5. Market Attractiveness/Growth Potential Analysis by End Users
6. Global Carrier Screening Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Carrier Screening Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Carrier Screening Demand Share Forecast, 2019-2026
7. North America Carrier Screening Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Carrier Screening Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Carrier Screening Market Size and Volume Forecast by End Users
7.4.1. Reference Laboratories
7.4.2. Clinics
7.4.3. Hospitals
7.4.4. Physicians
7.4.5. Others
7.5. Basis Point Share (BPS) Analysis by End Users
7.6. Y-o-Y Growth Projections by End Users
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Carrier Screening Demand Share Forecast, 2019-2026
8. Latin America Carrier Screening Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Carrier Screening Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Carrier Screening Market Size and Volume Forecast by End Users
8.4.1. Reference Laboratories
8.4.2. Clinics
8.4.3. Hospitals
8.4.4. Physicians
8.4.5. Others
8.5. Basis Point Share (BPS) Analysis by End Users
8.6. Y-o-Y Growth Projections by End Users
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Carrier Screening Demand Share Forecast, 2019-2026
9. Europe Carrier Screening Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Carrier Screening Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Carrier Screening Market Size and Volume Forecast by End Users
9.4.1. Reference Laboratories
9.4.2. Clinics
9.4.3. Hospitals
9.4.4. Physicians
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by End Users
9.6. Y-o-Y Growth Projections by End Users
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Carrier Screening Demand Share Forecast, 2019-2026
10. Asia Pacific Carrier Screening Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Carrier Screening Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Carrier Screening Market Size and Volume Forecast by End Users
10.4.1. Reference Laboratories
10.4.2. Clinics
10.4.3. Hospitals
10.4.4. Physicians
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by End Users
10.6. Y-o-Y Growth Projections by End Users
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Carrier Screening Demand Share Forecast, 2019-2026
11. Middle East & Africa Carrier Screening Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Carrier Screening Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Carrier Screening Market Size and Volume Forecast by End Users
11.4.1. Reference Laboratories
11.4.2. Clinics
11.4.3. Hospitals
11.4.4. Physicians
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by End Users
11.6. Y-o-Y Growth Projections by End Users
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Carrier Screening Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Carrier Screening Market: Market Share Analysis
12.2. Carrier Screening Distributors and Customers
12.3. Carrier Screening Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. GRAIL, LLC.
12.4.2. Bio-Techne
12.4.3. ASURAGEN, INC.
12.4.4. Laboratory Corporation of America Holdings
12.4.5. Otogenetics
12.4.6. Thermo Fisher Scientific Inc.
12.4.7. Myriad Genetics, Inc.
12.4.8. Natera, Inc.
12.4.9. Cepheid
12.4.10. F.Hoffmann-La Roche Ltd.
12.4.11. MedGenome
12.4.12. GeneTech
12.4.13. CENTOGENE N.V.
12.4.14. Autogenomics Inc.
12.4.15. Danaher Corporation
12.4.16. Eurofins Scientific
12.4.17. 23Andme Inc.
12.4.18. Abbott Laboratories
12.4.19. Oxford Nanopore
12.4.20. Illumina